• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    Cretex Companies CEO Steps Down

    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread

    Endoscopic Hemostasis Devices Market Valued at $730 Million

    Henry Schein Buys Majority Interest in Prism Medical Products

    Boston Scientific's Vercise Genus DBS Earns FDA Approval
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Fixing Face Mask Form and Function

    The Heart of the Matter: Trends in Cardiology

    Virtually the Same? The Challenges of Online Conferences

    Digital Health Delivers During a Year for the Ages

    Advanced Technology for Staking and Swaging Medical Plastics
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Concise Engineering

    K-Tube Technologies

    Medicoil

    Creganna Medical, part of TE Connectivity

    PTI Engineered Plastics Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Meeting Critical Ventilator Product Requirements Amid Pandemic

    Impact of COVID-19 on the Medtech Supply Chain

    Finding the Upside to a Challenging Year

    Preparing Your Design Controls for FDA Approval

    A 'Trial and Error' Approach to Micromolded Parts
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    maxon

    Medicoil

    Spectrum Plastics Group

    Concise Engineering

    Creganna Medical, part of TE Connectivity
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Improvements to Medicare’s NTAP for New, Innovative Medical Devices

    ...

    Improvements to Medicare’s NTAP for New, Innovative Medical Devices
    Related CONTENT
    • Congress Examines Additional COVID-19 Relief and Recent Regulatory Changes
    • Six Reimbursement Tips For Medtech Manufacturers
    • FDA OKs Luminex's NxTAG CoV Extended Panel to Detect SARS-CoV-2
    • Reimbursement and Access 2020
    • Early Screening Technology Helps Reduce Risk of Liver Disease
    Jeffrey J. Kimbell and Caroline P. Tucker, Jeffrey J. Kimbell & Associates Inc.04.03.19
    The new technology add-on payment (NTAP) program is a payment system designed by Congress to encourage the uptake of new and costly medical technologies1 in the hospital setting under the Hospital Inpatient Prospective Payment System (IPPS) in Medicare Part A. The IPPS, implemented in 1983, created a fixed, prospective payment for hospitalizations based on the average resources needed to treat a beneficiary with a particular diagnosis, or Medicare Severity-Diagnosis Related Group (MS-DRG). While the Centers for Medicare and Medicaid Services (CMS) revises MS-DRG rates annually, the agency bases these payments on Medicare claims data accrued over a two to three-year period. The result is a “payment lag,” or discrepancy between the current beneficiary profile and estimated beneficiary profile. The NTAP program, therefore, was created out of a growing recognition that the IPPS was unable to provide timely access and adequate payment to new, clinically significant technologies for Medicare beneficiaries.

    NTAP, signed into law in 2001, was intended to apply to new medical technology and drugs with demonstrated benefits over existing therapies for two to three years if the payment for the service or procedure related to the technology was inadequate, as well as classify that technology within a new or existing DRG with reimbursement that adequately reflects the cost of the procedure and technology at the conclusion of NTAP.2 CMS used its discretionary authority to issue regulations to determine a process for issuing add-on payments for new medical services and technology. For a new technology to be eligible for an NTAP, CMS requires three specific criteria be met, as mandated in the statute: the medical service or technology must be new; it must be costly such that the DRG rate otherwise applicable to discharges involving the medical service or technology is determined to be inadequate; and it must demonstrate a substantial clinical improvement over existing services or technologies.3

    If a device satisfies the three NTAP criteria, it is then eligible for an NTAP, where the payment rate is equal to the lesser of 1) 50 percent of the amount by which the total covered costs of the case exceed the MS-DRG payment, or 2) 50 percent of the costs of the new technology.4 As the cost of a new technology is reflected in subsequent recalibrations of the MS-DRG weights, the NTAP for such a technology is discontinued.

    Concern #1: Lack of NTAP Approvals
    As new technologies are rapidly being developed, tested, approved, and brought to market, NTAP applications and approvals have not kept pace with medical innovation. From 2012-2018, for example, only 26 medical device NTAP applications were submitted to CMS.5 This is compared to at least 250 medical devices that have either been cleared or approved by the U.S. Food and Drug Administration (FDA) during that same period.6

    In addition to low application rates, CMS denies a large proportion of NTAP applications each year. Of the 26 medical device manufacturers that had applied for NTAPs between fiscal year (FY) 2012 and 2018, only 11 were approved—a 42 percent acceptance rate. This trend can also be observed throughout the program’s history: between 2001 and 2011, CMS had only approved about a third—16 of 46, or 35 percent—of applications for NTAP.7 The most cited reasons for rejection are failure to meet the “newness” criterion and the “substantial clinical improvement” criterion.

    Concern #2: Payment Inadequacy
    While NTAP is intended to create a more certain reimbursement mechanism for innovative technologies, the payment amount associated with the NTAP is inadequate. Consider, for example, a technology that costs $5,000 and the MS-DRG associated with that technology reimburses at a rate of $30,000. Three scenarios are plausible: if the total cost of a case is $10,000, CMS will provide no NTAP (as the cost of the case is less than the MS-DRG payment); if the cost of a case is $50,000, CMS will provide an NTAP of $2,500 (or the lesser of 50 percent of the cost of the technology, $2,500, or 50 percent of the excess cost of the case not covered under the MS-DRG, $10,000); if the cost of the case is $31,000, CMS will provide an NTAP of $500 (or the lesser of 50 percent of the cost of the technology, $2,500, or 50 percent of the excess cost of the case not covered under the MS-DRG, $500).4 The NTAP payment of 50 percent falls well below the 80 percent payment associated with Medicare outlier payments.8 The inadequacy of the payment rates can put significant strain on hospitals using the new devices—where at least 50 percent of the cost of the device will not be recouped—as well as companies investing in, developing, and selling these technologies.

    In addition, NTAP payment rates are not comparable to similar payments made under other payment systems. Transitional pass-through payments are made under the Medicare Outpatient Prospective Payment System (OPPS) and function as an outpatient analog for NTAP—where a temporary payment is made for new devices while accurate cost data is collected to incorporate the cost of the device into the procedure. One of the most important aspects of the pass-through payment system, especially in the context of NTAP, is the payment amount for eligible devices, where new technologies are reimbursed at-cost during their pass-through payment period. One key difference between pass-through and NTAP is that pass-through is budget neutral, meaning it has built-in cost containment mechanisms, whereas NTAP is not budget neutral and changes to NTAP may result in substantial costs to Medicare.

    Financial Impact of NTAP
    Due to the limited number of NTAP approvals and the payments associated with them, NTAP has cost far less than the Congressional Budget Office (CBO) had originally projected, even without being budget neutral. When NTAP was originally enacted, CBO had projected 10-year costs of NTAP in the Medicare program to be $500 million. From 2002 to 2013, however, the NTAP program resulted in only $201.7 million in payments made by Medicare—40 percent of what CBO had predicted.9 Other analyses using data from the Medicare Provider Analysis and Review (MEDPAR) File, which contains information on all the Medicare beneficiaries using hospital inpatient services and expenditures for those services, has provided insight as to how NTAPs influence Medicare Part A spending. NTAPs, including both drug and device NTAPs in the MEDPAR analysis, were only applied to 0.02 percent of hospital discharges in FY 2013—with NTAP reimbursement at $14,491,792 compared to a total inpatient reimbursement amount of $127,729,044,215—and 0.03 percent in FY 2014—with NTAP reimbursement at $18,225,759 compared to a total inpatient reimbursement amount of $126,559,985,228.10

    Potential Legislative Action
    There are a few legislative proposals in Congress that seek to improve the NTAP program so patients have timely access to new and innovative medical technology. In the previous Congress, Rep. Tom Reed (R-NY) introduced H.R. 4679, the Ensuring Equal Access to Treatment Act. Reed’s bill would increase the NTAP payment amount from 50 percent to 75 percent; increase the NTAP add-on and data collection period from two or three years to five years to more adequately capture utilization; and establish a formal NTAP appeals process for manufacturers who were denied NTAP determinations. Additionally, in June 2018, Rep. Suzan DelBene (D-WA) introduced H.R. 5997, the Ensuring Patient Access to Critical Breakthrough Products Act. DelBene’s bill would increase the NTAP payment amount from 50 percent to 80 percent to align with the Medicare outlier payment rate; expand certain NTAP criteria definitions so more new technologies are eligible for and receive the add-on; and establish a formal appeals process for manufacturers denied an NTAP determination. While neither of these proposals is active legislation, they are examples of ways in which Congress can act to further medical innovation. DelBene is expected to release a new version of her bill for the current Congress this year, though the provisions contained in that bill are still uncertain.

    Policy Suggestions Going Forward
    As evidenced in this article, the current NTAP program has not been utilized or updated sufficiently. To preserve the original integrity of the NTAP program—to encourage the uptake of new, costly technologies by creating a temporary, but predictable, reimbursement for NTAP technologies until they can be incorporated into a traditional MS-DRG—Congress should consider increasing the add-on payment rate to incentivize appropriate uptake of new technologies. Congress, for example, could increase the payment rate to at least 75 percent or 80 percent, as evidenced in potential legislation, or up to 100 percent, as seen in the pass-through program. In addition, Congress and CMS should continue to work toward greater transparency when defining NTAP’s criteria, so that Medicare patients can benefit from promising, emerging technologies. 

    References/Endnotes
    1. While NTAPs are permitted for medical technologies (including medical devices), drugs, and biologicals, only medical technologies, and applicable policy concerns, are included in this article.
    2. Thomas WM. Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000. 2000; Sec. 533 (106th Congress, Second Session).
    3. § 42 CFR 412.87 (2001).
    4. Bockstedt L. The effect of Medicare’s new technology add-on payment. University of Minnesota (2010).
    5. This data, as well as the number of CMS acceptances, was taken from the FY 2012 through FY 2018 Medicare IPPS Proposed and Final Rules.
    6. FDA maintains an archive of cleared or approved medical devices on its website. Product approvals are listed per year, and each list contains a disclaimer that it may not include every new medical device that has been cleared or approved for sale in the United States. It is important to note that not all cleared or approved devices are used in inpatient procedures, as is a requirement to be eligible for NTAP, but this data is intended to show the low number of NTAP applications compared to available new devices on the market.
    7. Young K. Medicare Rejects Most Bids for New Technology Add-On Payment. Commonwealth Fund (2015).
    8. Congress created Medicare outlier payments to Medicare-participating hospitals in addition to the standard prospective payments for cases incurring extraordinarily high costs. To qualify for outlier payments, a case must have costs above a fixed-loss cost threshold amount (a dollar amount by which the costs of a case must exceed payments to qualify for outliers). Often, hospitals that use an NTAP technology seek out and receive outlier payments to supplement the costs not covered by the NTAP.
    9. Hernandez J, Machacz SF, Robinson JC. US Hospital Payment Adjustments For Innovative Technology Lag Behind Those In Germany, France, And Japan. Health Affairs (2006).
    10. Littmann N. CMS Reveals Rationale for NTAP Decisions in Rule Making. MedTech Intelligence (2015).

    Jeffrey J. Kimbell, president and founder of Jeffrey J. Kimbell & Associates Inc., represents 35 clients in the life sciences community seeking legislative and policy remedies in Washington. Founded in 1998, the firm provides strategic solutions to hand-selected clients seeking creation, modification, or proper implementation of public law.

    Caroline P. Tucker is a manager of health policy and reimbursement strategy at Jeffrey J. Kimbell & Associates Inc. She graduated with a B.A. in the history of science and medicine from the Johns Hopkins University and with an M.S. in health policy from the Milken Institute School of Public Health at the George Washington University.
    Related Searches
    • medical device manufacturers
    • medical
    • germany
    • protection
    Suggested For You
    Congress Examines Additional COVID-19 Relief and Recent Regulatory Changes Congress Examines Additional COVID-19 Relief and Recent Regulatory Changes
    Six Reimbursement Tips For Medtech Manufacturers Six Reimbursement Tips For Medtech Manufacturers
    FDA OKs Luminex FDA OKs Luminex's NxTAG CoV Extended Panel to Detect SARS-CoV-2
    Reimbursement and Access 2020 Reimbursement and Access 2020
    Early Screening Technology Helps Reduce Risk of Liver Disease Early Screening Technology Helps Reduce Risk of Liver Disease
    The Other Side of the Socialized Medicine Story The Other Side of the Socialized Medicine Story
    RFPi Receives FDA Clearance to Market iCertainty Blood Flow and Perfusion Imaging Medical Device RFPi Receives FDA Clearance to Market iCertainty Blood Flow and Perfusion Imaging Medical Device
    U.S. Joins False Claims Suit Against Arriva Medical & Alere U.S. Joins False Claims Suit Against Arriva Medical & Alere
    Medtronic Comments on Revised IN.PACT Post Market Study Data Medtronic Comments on Revised IN.PACT Post Market Study Data
    Shimmer Shimmer's Verisense Wearable Provides Biometric Data for Clinical Trials
    Discerning Medtech’s Path in 2019 Discerning Medtech’s Path in 2019
    Election Impact and the Beginning of the 116th Congress Election Impact and the Beginning of the 116th Congress
    Medtech and The Management Top 250 Medtech and The Management Top 250
    BioCardia Submits 510(k) Application for AVANCE Steerable Introducer for Transseptal Heart Access BioCardia Submits 510(k) Application for AVANCE Steerable Introducer for Transseptal Heart Access
    Graphene Can Hear Your Brain Whisper Graphene Can Hear Your Brain Whisper

    Related Columns

    • Fixing Face Mask Form and Function

      Fixing Face Mask Form and Function

      Masks for the general public are varied in both style and effectiveness.
      Sam Brusco, Associate Editor 11.04.20

    • Cardiovascular
      The Heart of the Matter: Trends in Cardiology

      The Heart of the Matter: Trends in Cardiology

      Of the three major segments of coronary stents, bioabsorbable stents are expected to have the highest growth between now and 2022.
      Maria Shepherd, President and Founder, Medi-Vantage 11.04.20

    • Virtually the Same? The Challenges of Online Conferences

      Virtually the Same? The Challenges of Online Conferences

      Like everyone else on the planet, I’m turning increasingly to virtual solutions to our physical challenges in the midst of a pandemic.
      Dawn A. Lissy, Founder & President, Empirical 11.04.20


    • Digital Health
      Digital Health Delivers During a Year for the Ages

      Digital Health Delivers During a Year for the Ages

      Internet of Medical Things technologies have emerged as the key enabler of a much more holistic and complete disease-state management toolbox.
      Brad Womble, Senior Director of Strategy, Marketing, and Mergers & Acquisitions, Jabil Healthcare 11.04.20

    • Advanced Technology for Staking and Swaging Medical Plastics

      Advanced Technology for Staking and Swaging Medical Plastics

      It reliably assembles heat- and vibration-sensitive components, and works with a wide range of plastic materials.
      Priyank Kishor, Global Product Manager—PulseStaking, Branson at Emerson 11.04.20

    • Quality Assurance When Supply Chain Disruptions Arise

      Quality Assurance When Supply Chain Disruptions Arise

      From supply chain disruptions to impromptu manufacturing modifications, the medical device industry has faced a whirlwind of complications in 2020.
      Sandi Schaible and Peter Steen, WuXi AppTec Medical Device Testing 11.04.20


    • The Top 30 and M&A in 2021: What’s Next?

      The Top 30 and M&A in 2021: What’s Next?

      With three of the top five companies appointing new CEOs in the last year and the global pandemic eroding earnings, M&A strategies could look a lot different.
      Florence Joffroy-Black and Dave Sheppard, MedWorld Advisors 11.04.20

    • COVID 19: Supply Chain Professionals’ Ultimate Reality Challenge

      COVID 19: Supply Chain Professionals’ Ultimate Reality Challenge

      Having been a part of the medtech supply chain for 40 years, I can say there has never been a more difficult time for supply chain professionals.
      Chris Oleksy, Founder and CEO, Oleksy Enterprises and Next Life Medical; CEO, Emergent Respiratory 11.04.20

    • Congress Examines Additional COVID-19 Relief and Recent Regulatory Changes

      Congress Examines Additional COVID-19 Relief and Recent Regulatory Changes

      The legislative year is nearly coming to a close as Washington survives yet another tumultuous election cycle.
      Jeffrey J. Kimbell, Eric P. Juhl, JD and David C. Rudloff, Jeffrey J. Kimbell & Associates Inc. 11.04.20


    • 3D/Additive Manufacturing
      Additive Manufacturing: Debinding Fluids Must-Haves

      Additive Manufacturing: Debinding Fluids Must-Haves

      As the pressure to produce more complex biomedical parts increases, medical device manufacturing using 3D printing is gaining widespread acceptance.
      Venesia Hurtubise, Technical Chemist, MicroCare Medical 11.04.20

    • Diagnostics
       How COVID-19 is Reshaping the Diagnostics Testing Sector

      How COVID-19 is Reshaping the Diagnostics Testing Sector

      The short-term impact on the diagnostics sector is readily apparent as the pandemic has fueled overwhelming demand for effective SARS-CoV-2 testing solutions.
      Eric Williams, Managing Director, Capstone Headwaters 11.04.20

    • Will Industry’s COVID-19 Recovery End Prematurely?

      Will Industry’s COVID-19 Recovery End Prematurely?

      Finally, a light at the end of the tunnel, but will it remain lit?
      Michael Barbella, Managing Editor 10.01.20


    • Surgical
      Hype or Hope? The Future of Surgical Robotics

      Hype or Hope? The Future of Surgical Robotics

      Recent publications suggest the U.S. performs more robotic surgery than every other country in the world.
      Maria Shepherd, President and Founder, Medi-Vantage 10.01.20

    • COVID Community: How the Pandemic Is Bringing Out the Best in Us

      COVID Community: How the Pandemic Is Bringing Out the Best in Us

      Given the brain power and generosity of our industry, I knew I could follow the wisdom of Fred Rogers’ mother and “look for the helpers.”
      Dawn A. Lissy, Founder & President, Empirical 10.01.20

    • Electronics
      Why Applying Cleanliness Standards to Outsourced Medical Electronics Is Important

      Why Applying Cleanliness Standards to Outsourced Medical Electronics Is Important

      When looking to outsource the manufacture of electronic medical devices, cleanliness standards and processes should be a top consideration.
      Jay Tourigny, Senior Vice President, MicroCare Medical 10.01.20


    Trending
    • Masimo Earns CE Mark For New Fingertip Pulse Oximeter
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • Understanding Food-Grade Vs. Biocompatibility For Medical Device Materials
    • Telemedicine, Regulatory Changes To Characterize Medtech Industry In 2021
    • Medtech Matters: Surgeons Scrubbing In Virtually
    Breaking News
    • Cretex Companies CEO Steps Down
    • Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    • Endoscopic Hemostasis Devices Market Valued at $730 Million
    • Henry Schein Buys Majority Interest in Prism Medical Products
    • Boston Scientific's Vercise Genus DBS Earns FDA Approval
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Pharmaceutical Focus: A Look at Combination Products
    • The Printed World: Additive Manufacturing in Medtech
    • The Lost Year: 2020 Year in Review
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login